Acurx Pharmaceuticals Inc. (ACXP)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Acurx Pharmaceuticals Statistics
Share Statistics
Acurx Pharmaceuticals has 19.53M shares outstanding. The number of shares has increased by 16.76% in one year.
Shares Outstanding | 19.53M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 3.99% |
Owned by Institutions (%) | n/a |
Shares Floating | 16.56M |
Failed to Deliver (FTD) Shares | 1.75K |
FTD / Avg. Volume | 0.61% |
Short Selling Information
The latest short interest is 474.48K, so 2.43% of the outstanding shares have been sold short.
Short Interest | 474.48K |
Short % of Shares Out | 2.43% |
Short % of Float | 2.87% |
Short Ratio (days to cover) | 12.59 |
Valuation Ratios
The PE ratio is -3.33 and the forward PE ratio is -0.38.
PE Ratio | -3.33 |
Forward PE | -0.38 |
PS Ratio | 0 |
Forward PS | 52.9 |
PB Ratio | 10.4 |
P/FCF Ratio | -4.95 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acurx Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.
Current Ratio | 2.53 |
Quick Ratio | 2.53 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.12% and return on capital (ROIC) is -312.38%.
Return on Equity (ROE) | -3.12% |
Return on Assets (ROA) | -1.89% |
Return on Capital (ROIC) | -312.38% |
Revenue Per Employee | 0 |
Profits Per Employee | -3.64M |
Employee Count | 4 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -74.92% in the last 52 weeks. The beta is -1.72, so Acurx Pharmaceuticals 's price volatility has been lower than the market average.
Beta | -1.72 |
52-Week Price Change | -74.92% |
50-Day Moving Average | 0.83 |
200-Day Moving Average | 1.78 |
Relative Strength Index (RSI) | 42.89 |
Average Volume (20 Days) | 286.99K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -14.58M |
Net Income | -14.58M |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has 7.47M in cash and 0 in debt, giving a net cash position of 7.47M.
Cash & Cash Equivalents | 7.47M |
Total Debt | 0 |
Net Cash | 7.47M |
Retained Earnings | -53.22M |
Total Assets | 5.98M |
Working Capital | -3.31B |
Cash Flow
In the last 12 months, operating cash flow was -9.80M and capital expenditures 5, giving a free cash flow of -9.80M.
Operating Cash Flow | -9.80M |
Capital Expenditures | 5 |
Free Cash Flow | -9.80M |
FCF Per Share | -0.77 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ACXP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -153.33% |
FCF Yield | -67.14% |
Analyst Forecast
The average price target for ACXP is $12, which is 1500% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 1500% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | -686.57 |
Piotroski F-Score | 1 |